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ABSTRACT
OBJECTIVE: Intravenous immunoglobulin (IVIG) is known to confer significant benefit in
rheumatological conditions including inflammatory myopathy. This study is aimed to assess
efficacy of IVIG across different aspects of internal organ involvement in refractory active
systemic sclerosis (SSc) particularly the gastrointestinal system.
METHODS: SSc patients with overlap polymyositis who remained active and unresponsive to
conventional disease-modifying agents and who subsequently received IVIG were identified.
Gastrointestinal symptoms were assessed using validated questionnaires. Medical Research
Council (MRC) Sum Score for muscle strength and Modified Rodnan Skin Score (mRSS) were
assessed. Serial measurements were undertaken at baseline prior to first IVIG and post
treatment in the most recent assessment.
RESULTS: Fifteen SSc patients were consecutively recruited into this observational study.
Mean duration of IVIG treatment was 2.3 years with treatment frequency ranging from 6
weekly to 4 monthly. Compared to baseline, there was significant reduction in gastro-
oesophageal reflux frequency and intensity mean scores (p=0.006 and p=0.013,
respectively). Significant improvement in GIT 2.0 score from baseline mean score (±SD) 1.07
± 0.67 to 0.60 ± 0.46 (p=0.002) was observed. There was regression in markers of muscle
disease with reduction in mean (±SD) MRC Sum Score and median creatine kinase level
(p=0.001 and p=0.025, respectively). Significant amelioration of mean basal mRSS (±SD),
21.5 ± 13.8 to 10 ± 10.6 (p=0.005) was observed.
CONCLUSION: IVIG may be a helpful adjunctive therapy in amelioration of some key clinical
aspects in refractory SSc. Sustained benefit from IVIG suggests specific immunomodulatory
effect on those with established SSc gastrointestinal complications.
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KEY MESSAGES
1) Long-term IVIG therapy provides benefit in amelioration of some key clinical aspects
in refractory SSc.
2) SSc patients with both upper and lower gastrointestinal manifestations had
significant improvement with IVIG therapy.
3) Our data supports potential benefit for immunomodulation with IVIG therapy in
established SSc gastrointestinal complications.
INTRODUCTION
Systemic sclerosis (SSc) is an uncommon autoimmune rheumatic with the pathological
hallmark of fibrosis with excessive collagen deposition and accumulation in skin and internal
organs [1]. The treatment of SSc using immunotherapies is targeted towards managing the
organ based complications, mainly by alteration of vascular and fibrotic damage secondary
to immune activation, which is central to SSc pathogenesis.The treatment of systemic
sclerosis (SSc) using immunotherapies is targeted towards managing organ based
complications. A number of cytotoxic agents and immunomodulatory therapies are used in
the treatment of SSc The organ-based treatment using immunosuppressive agents is aimed
to be started as early as possible to slow down the disease progression and to reduce the
severity of the complications. A number of cytotoxic agents and immunomodulatory
therapies are used in the treatment of SSc include cyclophosphamide, methotrexate,
mycophenolate mofetil (MMF) and autologous hematopoietic stem cell transplantation [2-
4]. These immunotherapies are being used with varying degrees of efficacy and with
inconsistent results, with some patients being refractory to these conventional approaches
[2-4].. Balancing potential clinical benefit with the known risks of immunosuppression is an
important aspect of management. The use of IVIG in SSc has been evaluated mostly in case
series and small uncontrolled studies, particularly assessing the improvement in skin fibrosis
and inflammatory myopathy overlap in SSc [9-14]. It is generally considered a safe
immunomodulatory therapy in routine use for a wide range of immune-mediated conditions
[6-8].
Intravenous immunoglobulin (IVIG) contains pooled, polyvalent IgG antibodies extracted
from plasma from more than 10,000 blood or plasma donations [5]. It is generally
considered a safe immunomodulatory therapy in routine use for a wide range of immune-
mediated conditions, such as idiopathic thrombocytopenic purpura, immunobullous
diseases and chronic inflammatory demyelinating polyneuropathy [6-8]. The use of IVIG in
SSc has been evaluated mostly in case series and small uncontrolled studies, particularly
assessing the improvement in skin fibrosis [9-12]. It is also known to have beneficial effects
in rheumatological conditions with inflammatory myopathy including myositis overlap in SSc
[13, 14]. Given the heterogeneity of the various rheumatological and neurological diseases
that respond to IVIG, it is probable that different autoimmune-related specific pathways
mediate the efficacy of this treatment for each disease.
There are few postulated mode of actions of IVIG in SSc. One of them is by iInhibition of
effector function of activated T cells and released cytokines, complement pathway
inhibition, Fcy receptor blockade and immunomodulation of lymphocyte differentiation are
few postulated mode of actions of IVIG in SSc [15-19]. or on its competition with MHC
molecules. NNeutralization of circulating autoantibodies by antibodies in immunoglobulins
is also is also believed to take place. Others include complement pathway inhibition, Fcy
receptor blockade or induction of inhibitory Fcy receptor on the surfaces of macrophages
and B cells by IgG binding, immunomodulation of lymphocyte differentiation and cytokine
synthesis [15-19]. Another possible explanation of the beneficial effect of IVIG effect on
fibroblasts is by blocking the activity of Fas through inhibition of fibrogenesis, by the
presence of anti-Fas antibodies in the IVIG preparations [20].
Gastrointestinal (GI) involvement in SSc is frequent [21] and can be severe with some
patients having the most common manifestation in SSc, seen in up to 90% of the patients
[21]. One of the major comorbidities associated with SSc is GI disease that may result in
severe life-threatening complications with pseudo-obstruction, malabsorption and
malnutrition. in some cases. Considering the limited evidence available to suggest potential
benefit of IVIG in SSc and recent case reports that suggested improvement in the GI aspect
of SSc that is typically refractory to other putative disease modifying treatment [9, 10, 22-
24], this present study aims to assess the efficacy of IVIG across different aspects of internal
organ involvement in refractory active SSc, particularly the GI complication. of the disease.
PATIENTS AND METHODS
All subjects included in this study were recruited from Centre for Rheumatology and
Connective Tissue Diseases at the Royal Free Hospital with clinical information recorded and
collected between March and November 2014. The study was approved by the London-
Hampstead NRES Committee (Project reference no: 6398) and was in compliance with the
WMA Declaration of Helsinki 2013. Fifteen SSc patients who remained unresponsive to
standard disease-modifying agents and subsequently received IVIG treatment on a regular
infusion basis were identified from the large cohort of more than 1400 SSc cases attending
our centre. All subjects fulfilled the 2013 EULAR/ American College of Rheumatology criteria
of SSc [25].and Iinformed consent to participate in the study was obtained. from all subjects.
The 15 SSc patients recruited were receiving IVIG treatment for inflammatory myopathy and
judged not to have achieved satisfactory clinical response to conventional
immunosuppressive agents.
Medical record review
Demographic, clinical and laboratory details were obtained from medical records review.
The subjects were classified as having either limited cutaneous SSc (lcSSc) or diffuse
cutaneous SSc (dcSSc). They were assessed at regular intervals either during their outpatient
appointments or at the time of IVIG treatment in our day care unit or inpatient admissions.
The presence of the following clinical features was determined: Raynaud’s, digital ulcer,
calcinosis, history of scleroderma renal crisis, lung fibrosis (extent of lung fibrosis >20% on
high resolution CT thorax with FVC <70%), pulmonary arterial hypertension (PAH), cardiac
involvement (direct cardiac involvement or secondary to PAH, lung fibrosis or kidney
disease) and myositis [26, 27]. Serial assessments of the following internal organ
involvement or clinical manifestation were undertaken at baseline prior to IVIG treatment
and post IVIG treatment.
Assessment of gastrointestinal symptoms
The upper and lower gastrointestinal symptoms were assessed using two validated
questionnaires, the Reflux Disease Questionnaire (RDQ) and UCLA SCTC GIT 2.0
questionnaire, which were self-administered [28-30]. The RDQ has been validated for its
utility in diagnosing gastro-oesophageal reflux disease (GORD) while the UCLA SCTC GIT 2.0
instrument has been validated for the use in SSc-associated GI involvement with good test-
retest reliability. These questionnaires were used for assessment of symptoms prior to
receiving the first IVIG infusion and the current symptoms while on IVIG treatment.
The UCLA SCTC GIT 2.0 questionnaire consists of seven items in which frequencies were
assessed in five categories of symptoms: reflux, distension, faecal soilage, diarrhoea, and
constipation, ; and the effects of symptoms on two categories: social functioning and
emotional well-being. The number of days affected by these symptoms during the previous
week was evaluated (divided in four scales: 0 days, 1-2 days, 3-4 days and 5-7 days). The
average score for each category was calculated and the average total score for all categories
were then determined. All the items other than constipation were used in the score.
Patients were instructed to provide the best answer they can even if they are unsure how to
answer a question.
In addition, RDQ was specifically used to assess gastroesophageal reflux disease (GORD).
gastroesophageal reflux disease (GORD). It consists of 6 components that evaluates the
frequency and intensity of three domains (heartburn, regurgitation and dyspepsia) during
the previous week. Each domain consists of two components. For each component, rating
was given by patient with sScore rangeding from 1 to 6 for frequency (not present to daily)
and severity (not present to severe). The mean score for each domain, RDQ frequency and
RDQ intensity was calculated. The higher scores indicate more frequent or severe severe or
frequent symptoms.
Assessment of muscle strength
Total Medical Research Council (MRC) Sum Score for muscle strength was evaluated and
calculated (0 to 60). prior to receiving IVIG and post IVIG treatment. A scale 0 to 5 assesses
the power of shoulder abductors, flexors of the elbow, hip and ankle, and extensors of the
wrist and knee. A total motor power score was calculated (MRC sum, 0 to 60).
Assessment of skin fibrosis
The extent of skin fibrosis was assessed using the modified Rodnan Skin Score (mRSS). Serial
mRSS prior to IVIG and available serial readings performed at end of each cycle were
assessed, including the current assessment.
Assessment of lung
FVC and DLCO (predicted %) were evaluated from lung function tests done. prior to first IVIG
treatment and available serial readings while on IVIG treatment.
Statistical analysis
All analyses were performed using SPSS version 19. Pearson and Spearman correlation test,
Pearson chi-square, test and Fisher exact test and Student’s T test were performed where
appropriate to test the associations and between categorical variables while the Student’s
T-test was used to compare continuous variables. p≤0.05 was considered as statistically 
significant. Pearson and Spearman correlation were used for assessment between disease
duration at IVIG initiation, duration of IVIG therapy, SSc disease duration and the response
status at the end of the study.
RESULTS
Clinical characteristics of SSc patients
The majority of patients were females (87%). Eleven (73.3%) patients had dcSSc. The clinical
charecteristics, IVIG treatment details and other treatment received for each patient were
summarised in Table 1. Mean (±SD) age was 47.3 ± 12 years. Mean (±SD) disease duration
from onset of first non-Raynauds symptoms was 7 ± 3.9 years. Mean duration of IVIG
treatment was 2.3 years (range 3 months to 11 years), with treatment frequency ranging
from 6 weekly to 4 monthly. All 15 patients received IVIG treatment for indication of
inflammatory myopathy, based on Peter and Bohan criteria [26, 27]. One patient received
IVIG for indication of chronic intestinal pseudo-obstruction in addition to inflammatory
myopathy. Three (20%) patients were positive for anti-ScL-70, another 3 (20%) for anti-RNA
Polymerase III antibody, while none of the patients had positive anti-centromere or PM-ScL
antibody. The others had positive antibody for SSA and SSB (one patient), nRNP (one
patient), U3 RNP (one patient), PL-7 (one patient) and Jo-1 (2 patients). The remaining 3
patients were negative for ENA testing. The 3 patients with PL-7 and Jo-1 antibodies had
cytoplasmic staining pattern in ANA. Five (33.3%) patients had lung fibrosis, 4 (26.6%)
patients had cardiac involvement, one had past history of renal crisis and none had PAH. All
patients were maintained on standard and optimal doses of proton-pump inhibitors (PPI),
histamine H2 receptor antagonist or prokinetic agents with or without in combination since
prior to initiation of IVIG. They also received immunosuppressive agents of standard dose.
14 patients received oral prednisolone. Nine patients were on MMF with the median dose
of 1500 mg daily, while in another 5 patients MMF was stopped. Nine patients were on
methotrexate, whereby in 6 out of these 9 patients methotrexate was later stopped. MMF
and methotrexate were stopped in these patients due to adverse reactions such as
leukopenia, liver impairment, GI side effects, varicella zoster and recurrent soft tissue
infections; except for two patients where the immunosuppressive agents did not seem to be
efficacious. Three patients were on hydroxychloroquine. Seven patients had previously
received intravenous cyclophosphamide pulses.
Assessment of internal organs following treatment with IVIG
Assessment of upper GI symptoms using RDQ
The mean values of frequency and intensity for GORD and each domain in the RDQ
assessment, (heartburn, dyspepsia and regurgitation), pre- and post IVIG treatment were
shown in Table 1.GIT 2.0 average score of each category and the average total score from
all categories, both pre- and post IVIG treatment were shown in Table 2. Compared to
baseline, there was significant improvement in GORD frequency mean scores (p=0.006).
Significant improvement was also observed in GORD intensity mean scores (p= 0.013). For
each domain, significant improvement was also seen.
Assessment of upper and lower GI symptoms using UCLA SCTC GIT 2.0 questionnaire
The average score of each category (reflux, distension, faecal soilage, diarrhoea, social
functioning and emotional well-being) and the average total score from all categories were
shown in Table 2. GIT 2.0 score improved significantly from baseline mean score (±SD) 1.07
± 0.67 to 0.60 ± 0.46 (p=0.002). Significant improvement was also observed in all the above
categories except for faecal soilage.
One patient with chronic intestinal pseudo-obstruction had improvement in abdominal
distension, diarrhoea, malabsorption, and electrolyte imbalance and feeding regime after
receiving IVIG. With IVIG treatment, the patient no longer received feeding via naso-
jejunostomy tube; and the frequency of total parenteral nutrition (TPN) was reduced from 7
days per week to four days per week.
Assessment of myopathy
Mean (±SD) baseline MRC Sum Score was 51.7 ± 3.6, which increased to 56.5 ± 2.9 (p=
0.001) at the end of the study. Baseline median creatine kinase level was 192 (range 35 to
3192) with significant reduction to 77 (range 42 to 465) (p=0.025). An EMG study in one
patient showed active myositis prior to first treatment of IVIG, with documented
improvement on subsequent EMG with reduced inflammatory potentials following the third
course of IVIG given six weeks apart between each course. Repeat EMG was not undertaken
for the remaining patients. IVIG conferred a steroid-sparing effect in 8 out of 13 (61.5%)
patients. The median dose reduction in oral prednisolone was 8.75 mg (range 2.5 to 17.5
mg). The fFrequency of IVIG treatment was reduced in all except in two patients, due to
improvement and stability of myopathy. These patients’ IVIG frequency was reduced from
the initial 4 weekly regime, gradually to 6 weekly, 8 weekly, 3 monthly or 4 monthly.
Assessment of skin fibrosis
There was significant amelioration of mean basal mRSS (±SD), 21.5 ± 13.8 to 10 ± 10.6
(p=0.005 at post-treatment). Mean basal mRSS assessment was undertaken at 1.5 years
prior to IVIG initiation (range 3 months to 5 years), while post treatment assessment was
performed at 3.4 years (range 3 months to 11 years).
Other assessments
No improvement in lung function parameters, FVC and DLCO was observed. Four out of
seven patients with digital ulcers (57.1%) reported reduction in frequency of digital ulcers
with no new digital ulcers in response to IVIG treatment. All seven patients were on oral
vasodilator treatment for Raynaud’s, including fivewith 5 out of 7 patients on Iloprost
infusion. treatment. Improvement and/or resolution of subcutaneous calcinosis were
reported in 3 out 5 (60%) patients. Disease duration at IVIG initiation, duration of IVIG
therapy and SSc disease duration were not associated with the response status at the end of
the study.
DISCUSSION
This observational study on a limited number of SSc patients with refractory inflammatory
myopathy shows that IVIG improved various clinical aspects including GI disease, myopathy
and skin fibrosis. Interestingly, oOur patients reported improvement in GI symptoms after
receiving IVIG treatment despite maximal gastro-protective and prokinetic agents. As there
is no evidence to suggest an immunomodulatory effect of currently available DMARDs on GI
disease in SSc, the current approach of management focuses on symptomatic relief and
supportive treatment with medication, diet modification, nutritional support and
occasionally surgical treatment in severe refractory cases. Therefore this promising
observation suggests that IVIG may be useful in a subset of SSc patients with severe and
debilitating GI disease.
Although individual cases have been reported, including two patients from our centre [24],
this is the first study to systematically assess the impact of IVIG treatment in the GI system
in SSc in a well characterised disease cohort, and to explore longer term outcomes in
extended follow-up. Both upper and lower GI involvement of SSc patients in the current
study had significant improvement with IVIG therapy in each domain except for faecal
soilage, in the two validated disease-specific GI outcome measures. Specifically, each of the
key components of RDQ demonstrated improvement in heartburn, dyspepsia and
regurgitation. There were significantly lower scores, in response to IVIG treatment, for each
key component of RDQ and all the items in the UCLA SCTC GIT 2.0 questionnaires , including
reflux, abdominal distension, diarrhoea and emotional well-being, with including a positive
trend observed for faecal soilage .(P=0.059). One patient had improvement in
manifestations of chronic intestinal pseudo-obstruction following IVIG treatment. Few case
reports in literature reported rResolution of the pseudo-obstruction secondary to various
autoimmune conditions after IVIG administration was previously reportedof IVIG [31, 32].
The use of IVIG has also been reported to be beneficial in polymyositis and dermatomyositis
patients with severe life-threatening oesophageal disorders [33].
The pathophysiology of GI abnormalities in SSc is not well understood, but is contributed to
both myogenic and neurogenic factors., as a consequence of initial vascular damage, leading
to inflammation, excessive collagen deposition in the submucosa and smooth muscle
atrophy [34, 35]. Immunological abnormalities are also implicated in its pathogenesis, for
example over-expression of profibrotic factors such as transforming growth factor-β (TGF-
β), endothelin-1 and connective tissue growth factor [36]. The end result is impaired 
peristaltic activity with various secondary problems such as GORD, delayed gastric
emptying, early satiety, abdominal distension, small intestine bacterial overgrowth,
incontinence and pseudo-obstruction. leading to malabsorption and malnutrition. It is not
known how IVIG works in improving the GI symptoms in SSc patients. Given the potential
benefit IVIG has on skin and inflammatory myopathy [9,14 11-14, 37, 38], it is likely that IVIG
possibly works in a similar way in the GI tract. In SSc fibroblasts, it is postulated that the
increased fibrotic tissue is due to overexpression of various growth factors including
interleukin-4 (IL-4) and TGF-β [39-42]. In addition to these profibrotic cytokines, SSc
fibroblasts also express excessive α-smooth muscle actin (α-SMA) and type 1 pro-collagen 
and less matrix metalloproteinase-1 (MMP-1)[38]. In an experimental study by Blank et al in
which IVIG was administered to tight skin mice, the effect on the profibrotic cytokines was
observed with downregulation of type 1 pro-collagen with decreased collagen deposition
[43]. The inhibitory effect on IL-4 and TGF-β was also reported following administration of 
IVIG [38, 43]. IVIG is also known to have a regulatory effect on MMP, thus potentially
promoting tissue repair [46].
Similarly, high amount of collagen type I and III in the lamina propria that increased towards
the muscularis mucosae were demonstrated on gastric samples from SSc patients with SSc.
In addition, tType IV collagen was present around the glands and small vessels of mucosa,
and this may lead to alteration in secretory function and vascular tone dysfunction. Strong
expression of several profibrotic factors such as TGF-β and myofibroblasts with increased α-
SMA were also observed in the gastric samples which might account for the increased
extracellular matrix synthesis and deposition [36].
In an experimental study by Blank et al in which IVIG was administered to tight skin mice for
four weeks (total dose: 2gm/kg), the effect on the profibrotic cytokines was observed with
downregulation of type 1 pro-collagen with decreased collagen deposition [43]. The
inhibitory effect on IL-4 and TGF-β was also reported following administration of IVIG [38, 
43]. In another study, both the affected sera and skin of SSc patients had increased
expression of IFN- and IL-12 after receiving IVIG treatment, suggesting a rebalance of
downregulated Th1 cytokines in SSc patients [44]. On the other hand, IVIG partially
abrogated TGF-β production by downregulation of T cells or by direct binding of IVIG to TGF-
β in a study conducted in patients with dermatomyositis [45]. The authors also reported 
reduced local expression of TGF-β in the muscles of patients who responded favourably to 
IVIG. IVIG is also known to have a regulatory effect on MMP; which are extra-cellular matrix
proteases enzymes, thus potentially promoting tissue repair [46].
In the GI tract, the intrinsic neurons in the myenteric plexus have an important role in the
contractile activity, with acetylcholine as the principle excitatory neurotransmitter acting via
the antimuscarinic-3-acetylcholine receptor (M3R). Interestingly, antibodies against M3R
were recently described in SSc patients with severe GI, suggesting a potential link with
dysmotility in SSc [47]. Another study identified presence of specific SSc IgG-M3R complex
on the smooth muscle cells of internal anal sphincter of rats. The immunoglobulins from SSc
patients resulted in significant inhibition of the M3R, which was reversible with antibody
removal. The authors suggested that SSc GI dysmotility may be caused by autoantibodies
blocking the muscarinic neurotransmission in the smooth muscle cells. Therefore a
treatment directed towards neutralization or removal of those antibodies may benefit the
SSc patients [48].
Some previous studies report possible efficacy of IVIG for skin sclerosis in SSc patients [9, 11,
12, 23, 38]. The effect of IVIG therapy was confirmed by improvement in the skin score
(mRSS) and histological examination of SSc skin samples [11, 38]. The positive results from
IVIG treatment was also further observed in skin samples of bleomycin-induced SSc murine
model, demonstrating downregulation of monocyte chemoattractant protein (MCP-1/CCL2)
and TGF-β production [49]. One randomized, double–blind, placebo-controlled A trial
involving 63 SSc patients demonstrated significant improvement in skin score in patients
receiving two courses of IVIG compared to patients receiving a single course, . There was
significant difference at week 60 with improvement in minimally important difference (MID)
estimates for mRSS, suggesting that multiple-course treatment over a specific duration may
be critical to assess efficacy of IVIG [10]. Our data is consistent with the reported results
with reduction in skin score by 11.5 ± 3.2 with repeat cycles of IVIG course.
Importantly, clinical improvement in inflammatory myopathy following IVIG treatment was
demonstrated in our patients, which is consistent with other reports [37, 50]. In this current
study tThe MRC sum score improved following each cycle of IVIG received, in addition to a
cumulative improvement in the score from the baseline of first cycle of IVIG. As the effect of
IVIG weaned in varying degrees in some patients, the courses of IVIG were administered at
an appropriate time to maintain response. Over time, the frequency of IVIG courses was
reduced in almost all patients as the disease stabilised. A minority of the patients noted a
subjective improvement in their digital ulcers following IVIG therapy, which may be
accounted by remodelling of the microvasculature pathology and fibrotic
microenvironment, eventually promoting the healing of ulcers.
The number of studies involving IVIG treatment in SSc is restricted largely to case reports.
There is currently no evidence that IVIG therapy halt the progression of GI disease in SSc.
IVIG, however was well tolerated in all of our patients without any significant side effects.
There are several limitations in this study. This study was not originally designed to assess
the effect of IVIG in GI manifestations; instead IVIG was administered for refractory
inflammatory myopathy.Our patients received variable numbers of repeat cycles of IVIG at
various time intervals; thus we did not perform objective assessments at specific time
intervals. We did not have SSc patients without myositis on IVIG treatment, therefore it
remains a matter of speculation whether the pathogenetic mechanisms underlying GI
involvement in the patients, partly might be related to myositis-specific pathogenetic
process itself and therefore could be more responsive to IVIG.Another drawback is that
using a subjective symptom questionnaire may not accurately describe actual disease
severity; therefore disease activity may have been underestimated. However, despite a
small sample size, our study has shown positive encouraging results in various SSc clinical
manifestations.
CONCLUSION
This study provides support that IVIG use is associated with improvement of clinical features
in SSc patients who have been refractory to other immunosuppressive therapies. This
approach warrants further prospective evaluation in a controlled trial and also suggests a
specific potential benefit for immunomodulation in established gastrointestinal
complications.
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Table 1. Demographic, clinical characteristics and treatment details of each patient
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Immunosuppressants received Lab values
Previous Current Hb
(g
/L
)
Al
b
(g
/L
)
CR
P
(m
g/
L)
1 19 18 F L SSA, SSB none 4 18 3 L MTX, infliximab MMF, HCQ, pred 10.3 43 2
2 54 53 M D ScL 70 cardiac SSc 5 13 4 L,R,D MMF, CYC MTX, pred 13.3 44 6
3 29 27 F D ScL 70 none 4 31 2 L,D MTX MMF, pred 13.3 39 5
4 54 49 F L nRNP PF 12 29 9 L,D MMF,HCQ pred 14.1 41 3
5 60 58 F D Jo-1 cardiac SSc 8 23 6 E,R,M,G MTX,HCQ, CYC, CSA, AZA MMF, pred 13.4 40 2
6 44 33 F D ScL 70 cardiac SSc, PF 12 135 2 L,R,D CYC, aza MMF, MTX, HCQ, pred 11.7 44 2
7 50 47 F D ANA +, ENA - none 4 33 1 L,D MMF pred 9 43 1
8 53 45 F D RNAP none 13 100 5 L,On,G MMF, MTX, CYC, CSA, pred none 11 48 6
9 46 45 F D RNAP none 3 13 2 L,R CYC MMF, pred 10.8 42 9
10 54 53 M D U3RNP cardiac SSc 5 3 5 L,R,M CYC MMF, pred 12.1 39 1
11 41 39 F D RNAP none 4 14 3 Ra MTX, AZA, rituximab MMF, HCQ, pred 10.5 48 2
12 49 40 F D ANA +, ENA - SRC 13 23 5 L,R None MMF, HCQ 11.7 49 1
13 43 42 F L PL-7 PF 5 3 5 O CYC MMF, pred 11 39 11
14 45 44 F D ANA +, ENA - PF 3 3 3 O MMF, tocilizumab MTX, pred 13 38 5
15 69 68 F L Jo-1 PF 10 5 10 O MTX, CSA pred 11.9 40 5
Abbreviations:
Systemic sclerosis (SSc), intravenous immunoglobulin (IVIG), gastrointestinal (GI), Laboratory (lab) values - haemoglobin (Hb), albumin (Alb), c-reactive protein (CRP);
Gender - male (M), female (F); Subset - limited cutaneous (L), diffuse cutaneous (D); Autoantibodies – ribonucleoprotein (RNP), anti-nuclear antibody (ANA), extra
nuclear antibody (ENA), RNA Polymerase (RNAP); Organ complications - pulmonary fibrosis (PF), scleroderma renal crisis (SRC); GI medication – lansoprazole (L),
esomeprazole (E), omeprazole (O), rabeprazole (Ra), ranitidine (R), gaviscon (G), domperidone (D), metoclopramide (M), Ondansetron (On); Immunosuppressants –
mycophenolate mofetil (MMF), methotrexate (MTX), hydroxychloroquine (HCQ), cyclophosphamide (CYC), ciclosporin (CSA), azathioprine (AZA), prednisolone (pred)
Table 2 Results of Reflux Disease Questionnaire (RDQ) and UCLA SCTC GIT 2.0 questionnaire pre- and post
treatment with IVIG
Mean score (±SD) p value (≤ 0.05) 
RDQ
GORD frequency pre-IVIG 3.19 ± 1.79
0.006GORD frequency post-IVIG 1.88 ± 0.90
Heartburn frequency pre-IVIG 2.83 ± 1.85
0.021Heartburn frequency post-IVIG 1.76 ± 0.99
Dyspepsia frequency pre-IVIG 3.16 ± 1.93
0.008Dyspepsia frequency post-IVIG 1.70 ± 0.97
Regurgitation frequency pre-IVIG 3.60 ± 1.81
0.007Regurgitation frequency post-IVIG 2.20 ± 1.16
GORD intensity pre-IVIG 3.03 ± 1.70
0.013GORD intensity post-IVIG 1.96 ± 0.86
Heartburn intensity pre-IVIG 2.73 ± 1.80
0.016Heartburn intensity post-IVIG 1.60 ± 0.71
Dyspepsia intensity pre-IVIG 2.80 ± 1.77
0.035Dyspepsia intensity post-IVIG 1.90 ± 0.91
Regurgitation intensity pre-IVIG 3.56 ± 1.79
0.013Regurgitation intensity pre-IVIG 2.40 ± 1.40
GIT 2.0 Questionnaire
Total GIT 2.0 score pre-IVIG 1.07 ± 0.67
0.002Total GIT 2.0 score post-IVIG 0.60 ± 0.46
Reflux pre-IVIG 1.52 ± 0.92
0.011Reflux post-IVIG 0.88 ± 0.62
Distension pre-IVIG 1.86 ± 0.79
0.003Distension post-IVIG 1.08 ± 0.67
Soilage pre-IVIG 0.66 ± 0.89
0.059Soilage post-IVIG 0.33 ± 0.61
Diarrhoea pre-IVIG 0.73± 0.70
0.026Diarrhoea post-IVIG 0.36 ± 0.63
Social functioning pre-IVIG 0.85 ± 0.90
0.146Social functioning post-IVIG 0.59 ± 0.60
Emotional well-being pre-IVIG 0.79 ± 1.03
0.050Emotional well-being post-IVIG 0.39 ± 0.69
Patient Total GIT 2.0 Score
Pre-IVIG (baseline) Post-IVIG (end of study)
1 0.041 0.096
2 0.617 0.596
3 0.575 0.318
4 1.021 0.878
5 0.992 0.058
6 0.846 0.659
7 1.583 1.041
8 2.155 0.193
9 2.547 1.81
10 1.411 1.089
11 1.596 0.341
12 0.834 0.67
13 0.547 0.575
14 0.916 0.534
15 0.417 0.166
